Novo Nordisk A/S (NYSE:NVO) Shares Down 0% – Time to Sell?

Novo Nordisk A/S (NYSE:NVO)’s stock price traded down 0% during mid-day trading on Tuesday . The company traded as low as $69.00 and last traded at $69.41. 1,612,654 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 8,313,432 shares. The stock had previously closed at $69.44.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NVO. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Stifel Nicolaus cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Finally, Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Trading Down 0.2 %

The company’s 50 day simple moving average is $81.64 and its two-hundred day simple moving average is $97.47. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $305.48 billion, a price-to-earnings ratio of 20.70, a P/E/G ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio is presently 47.72%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its stake in shares of Novo Nordisk A/S by 16.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 204,583 shares of the company’s stock valued at $24,360,000 after purchasing an additional 28,988 shares during the period. Benjamin Edwards Inc. boosted its stake in shares of Novo Nordisk A/S by 643.8% during the 3rd quarter. Benjamin Edwards Inc. now owns 25,697 shares of the company’s stock worth $3,060,000 after acquiring an additional 22,242 shares in the last quarter. Hilltop Holdings Inc. boosted its position in Novo Nordisk A/S by 103.3% during the third quarter. Hilltop Holdings Inc. now owns 7,978 shares of the company’s stock worth $950,000 after purchasing an additional 4,054 shares in the last quarter. Integrated Wealth Concepts LLC grew its holdings in Novo Nordisk A/S by 1.5% in the third quarter. Integrated Wealth Concepts LLC now owns 33,027 shares of the company’s stock valued at $3,933,000 after purchasing an additional 477 shares during the period. Finally, IHT Wealth Management LLC lifted its position in shares of Novo Nordisk A/S by 39.9% during the 3rd quarter. IHT Wealth Management LLC now owns 11,311 shares of the company’s stock valued at $1,343,000 after buying an additional 3,228 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.